KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Debt Issuances (2016 - 2021)

Jazz Pharmaceuticals has reported Long-Term Debt Issuances over the past 8 years, most recently at $2.2 billion for Q3 2021.

  • Quarterly Long-Term Debt Issuances rose 129.11% to $2.2 billion in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2022, changed 0.0% year-over-year, with the annual reading at $980.8 million for FY2024, N/A changed from the prior year.
  • Long-Term Debt Issuances was $2.2 billion for Q3 2021 at Jazz Pharmaceuticals, up from -$981.4 million in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $2.2 billion in Q3 2021 and troughed at -$981.4 million in Q4 2020.
  • The 3-year median for Long-Term Debt Issuances is $490.6 million (2017), against an average of $562.1 million.
  • Biggest five-year swings in Long-Term Debt Issuances: surged 30.0% in 2017 and later surged 129.11% in 2021.
  • Tracing JAZZ's Long-Term Debt Issuances over 3 years: stood at -$91000.0 in 2017, then tumbled by 1078340.66% to -$981.4 million in 2020, then soared by 329.11% to $2.2 billion in 2021.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $2.2 billion, -$981.4 million, and $981.4 million for Q3 2021, Q4 2020, and Q3 2020 respectively.